Literature DB >> 20033986

Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease.

Fabienne Brilot1, Russell C Dale, Rebecca C Selter, Verena Grummel, Sudhakar Reddy Kalluri, Muhammad Aslam, Verena Busch, Dun Zhou, Sabine Cepok, Bernhard Hemmer.   

Abstract

OBJECTIVE: Myelin oligodendrocyte glycoprotein (MOG) is a candidate target antigen in demyelinating diseases of the central nervous system (CNS). Although MOG is encephalitogenic in different animal models, the relevance of this antigen in human autoimmune diseases of the CNS is still controversial.
METHODS: We investigated the occurrence and biological activity of antibodies to native MOG (nMOG) in 47 children during a first episode of CNS demyelination (acute disseminated encephalomyelitis [ADEM], n = 19 and clinical isolated syndrome [CIS], n = 28) by a cell-based bioassay.
RESULTS: High serum immunoglobulin G (IgG) titers to nMOG were detected in 40% of children with CIS/ADEM but 0% of the control children affected by other neurological diseases, healthy children, or adults with inflammatory demyelinating diseases, respectively. By contrast, IgM antibodies to nMOG occurred in only 3 children affected by ADEM. Children with high anti-nMOG IgG titer were significantly younger than those with low IgG titer. Anti-nMOG IgG titers did not differ between the ADEM and CIS group, and did not predict conversion from CIS to MS during a mean 2-year follow-up. However, intrathecal IgG anti-MOG antibody synthesis was only seen in CIS children. IgG antibodies to nMOG not only bound to the extracellular domain of nMOG, but also induced natural killer cell-mediated killing of nMOG-expressing cells in vitro.
INTERPRETATION: Overall, these findings suggest nMOG as a major target of the humoral immune response in a subgroup of children affected by inflammatory demyelinating diseases of the CNS. Children may provide valuable insight into the earliest immune mechanisms of CNS demyelination.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20033986     DOI: 10.1002/ana.21916

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  84 in total

Review 1.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

2.  Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more.

Authors:  Marie Cathrin Mayer; Edgar Meinl
Journal:  Ther Adv Neurol Disord       Date:  2012-05       Impact factor: 6.570

3.  Clinical and MRI phenotype of children with MOG antibodies.

Authors:  Cristina Fernandez-Carbonell; David Vargas-Lowy; Alexander Musallam; Brian Healy; Katherine McLaughlin; Kai W Wucherpfennig; Tanuja Chitnis
Journal:  Mult Scler       Date:  2015-06-03       Impact factor: 6.312

4.  White matter disease: Roles of anti-MOG antibodies in demyelinating diseases.

Authors:  Tomas Olsson
Journal:  Nat Rev Neurol       Date:  2011-04-12       Impact factor: 42.937

Review 5.  [Demyelinating disorders].

Authors:  T Weber; W Köhler
Journal:  Nervenarzt       Date:  2010-04       Impact factor: 1.214

Review 6.  Detection of MOG-IgG by cell-based assay: moving from discovery to clinical practice.

Authors:  Amanda Marchionatti; Mark Woodhall; Patrick Joseph Waters; Douglas Kazutoshi Sato
Journal:  Neurol Sci       Date:  2020-10-15       Impact factor: 3.307

Review 7.  B cells in multiple sclerosis: connecting the dots.

Authors:  H-Christian von Büdingen; Amit Bar-Or; Scott S Zamvil
Journal:  Curr Opin Immunol       Date:  2011-10-07       Impact factor: 7.486

Review 8.  Experimental models of neuromyelitis optica: current status, challenges and future directions.

Authors:  Minshu Li; Yaping Yan
Journal:  Neurosci Bull       Date:  2015-06-24       Impact factor: 5.203

9.  Antibody binding to neuronal surface in Sydenham chorea, but not in PANDAS or Tourette syndrome.

Authors:  F Brilot; V Merheb; A Ding; T Murphy; R C Dale
Journal:  Neurology       Date:  2011-03-16       Impact factor: 9.910

10.  Serum autoantibodies to myelin peptides distinguish acute disseminated encephalomyelitis from relapsing-remitting multiple sclerosis.

Authors:  Keith Van Haren; Beren H Tomooka; Brian A Kidd; Brenda Banwell; Amit Bar-Or; Tanuja Chitnis; Silvia N Tenembaum; Daniela Pohl; Kevin Rostasy; Russell C Dale; Kevin C O'Connor; David A Hafler; Lawrence Steinman; William H Robinson
Journal:  Mult Scler       Date:  2013-04-23       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.